Reade revalidatie & reumatologie centrum te Amsterdam
- Address
- Admiraal Helfrichstraat 1, 1056 AA Amsterdam, The Netherlands
Reade Revalidatie & Reumatologie Centrum Amsterdam
Reade is a specialized rehabilitation and rheumatology center in Amsterdam dedicated to advancing the understanding and treatment of rheumatoid arthritis (RA) through innovative clinical research. The center focuses on optimizing therapeutic strategies and investigating the systemic effects of rheumatic diseases, particularly cardiovascular complications associated with inflammatory arthritis.
- Cardiovascular outcomes in rheumatoid arthritis patients, including cardiac function, myocardial inflammation, and coronary plaque morphology
- Janus Kinase (JAK) inhibitor therapy and its effects on heart health in RA patients
- Biologic therapy optimization, including dose optimization strategies for tocilizumab and therapeutic drug monitoring
The research center employs disease activity monitoring using standardized measures such as DAS28-ESR to evaluate treatment efficacy and guide personalized dosing strategies. By investigating the relationship between inflammatory arthritis and cardiovascular risk, Reade contributes to comprehensive patient care that addresses both joint disease and systemic complications in patients diagnosed according to ACR/EULAR classification criteria.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 20 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Sint Maartenskliniek Stichting3active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Sint Maartenskliniek Stichting3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Reade revalidatie & reumatologie centrum te Amsterdam
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Concentration-Guided Tocilizumab Dose Reduction Versus Standard Dosing in Rheumatoid Arthritis: A Randomized, International, Multicenter, Non-Inferiority Trial | Reade revalidatie & reumatologie centrum te Amsterdam | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 20 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Etanercept | 2 | Unknown | 2026-06-09 | 2026-06-09 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.